Lipid emulsions for parenterally fed preterm infants

Kapoor, Vishal; Malviya, Manoj N; Soll, Roger F.

doi:10.1002/14651858.cd013163.pub2

Cited by 44 publications

(47 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Total parenteral nutrition based on soybean lipid emulsion, which provides essential linoleic acid (LA) and gamma-linolenic acid, may not be adequate for preterm infants due to deficient downstream metabolic enzymes, and does not allow levels comparable to third trimester fetuses and term-born infants to be sustained [10]. However, 100% fish oil-based emulsions (Omegaven, Fresenius-Kabi, Bad Homburg, Germany) result in elevated DHA and EPA plasma levels, but negatively affect the level of AA, which is essential for brain and retina development as well as growth [13,44]. Newer-generation fish oil-based compound (SMOFLipid, Fresenius-Kabi) showed a benefit in decreasing BPD severity compared to an olive oil-based compound (ClinOleic, Baxter Healthcare SA, Wallisellen, Switzerland) in one small RCT [11], although another RCT failed to show any difference in BPD incidence [12].…”

Section: Lipidsmentioning

confidence: 99%

Nutrients and Microbiota in Lung Diseases of Prematurity: The Placenta-Gut-Lung Triangle

et al. 2020

View full text Add to dashboard Cite

Cardiorespiratory function is not only the foremost determinant of life after premature birth, but also a major factor of long-term outcomes. However, the path from placental disconnection to nutritional autonomy is enduring and challenging for the preterm infant and, at each step, will have profound influences on respiratory physiology and disease. Fluid and energy intake, specific nutrients such as amino-acids, lipids and vitamins, and their ways of administration —parenteral or enteral—have direct implications on lung tissue composition and cellular functions, thus affect lung development and homeostasis and contributing to acute and chronic respiratory disorders. In addition, metabolomic signatures have recently emerged as biomarkers of bronchopulmonary dysplasia and other neonatal diseases, suggesting a profound implication of specific metabolites such as amino-acids, acylcarnitine and fatty acids in lung injury and repair, inflammation and immune modulation. Recent advances have highlighted the profound influence of the microbiome on many short- and long-term outcomes in the preterm infant. Lung and intestinal microbiomes are deeply intricated, and nutrition plays a prominent role in their establishment and regulation. There is an emerging evidence that human milk prevents bronchopulmonary dysplasia in premature infants, potentially through microbiome composition and/or inflammation modulation. Restoring antibiotic therapy-mediated microbiome disruption is another potentially beneficial action of human milk, which can be in part emulated by pre- and probiotics and supplements. This review will explore the many facets of the gut-lung axis and its pathophysiology in acute and chronic respiratory disorders of the prematurely born infant, and explore established and innovative nutritional approaches for prevention and treatment.

show abstract

Section: Lipidsmentioning

confidence: 99%

Nutrients and Microbiota in Lung Diseases of Prematurity: The Placenta-Gut-Lung Triangle

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, there were no instances of raised BUN levels (14.3 mmol/L [26]) in either group (Supplementary Table 6, Additional File). Hypertriglyceridemia (> 2.25 mmol/L [27]) occurred in four infants, one each in the P-PN and control group on days 2 and 7 (Supplementary Table 6, Additional File). There were no significant differences between the groups for mean levels of serum albumin, pH, base excess and blood sugar (Supplementary Table 5, Additional File) nor in proportion of infants with low serum albumin, hyperglycaemia or metabolic acidosis (Supplementary Table 6, Additional File).…”

Section: Biochemistrymentioning

confidence: 99%

The efficacy and safety of peripheral intravenous parenteral nutrition vs 10% glucose in preterm infants born 30 to 33 weeks’ gestation: a randomised controlled trial

et al. 2020

View full text Add to dashboard Cite

Background: Preterm infants born 30 to 33 weeks' gestation often require early support with intravenous fluids because of respiratory distress, hypoglycemia or feed intolerance. When full feeds are anticipated to be reached within the first week, risks associated with intravenous delivery mode and type must be carefully considered. Recommendations are for parenteral nutrition to be infused via central venous lines (because of the high osmolarity), however, given the risks associated with central lines, clinicians may opt for 10% glucose via peripheral venous catheter when the need is short-term. We therefore compare a low osmolarity peripheral intravenous parenteral nutrition (P-PN) solution with peripheral intravenous 10% glucose on growth rate in preterm infants born 30 to 33 weeks' gestation. Methods: In this parallel group, single centre, superiority, non-blinded, randomised controlled trial, 92 (P-PN 42, control 50) infants born 30 + 0 to 33 + 6 weeks' gestation, were randomised within 24 h of age, to receive either P-PN (8% glucose, 30 g/L amino acids, 500 IU/L heparin and SMOFlipid®) or a control of peripheral intravenous 10% glucose. Both groups received enteral feeds according to hospital protocol. The primary outcome was rate of weight gain from birth to 21 days of age.

show abstract

“…Наприклад, ClinOleic -це ЖE на основі оливкової олії із співвідношенням 4: 1 оливкової до соєвої олії та однією третиною вмісту ПНЖК порівняно з СО-ЖЕ (наприклад,Intralipid). Також були розроблені ЖE, що містять риб'ячий жир (наприклад, Omegaven), які багаті ω-3 жирними кислотами і мають низьке співвідношення ω-6 до ω-3 [7][8][9][10][11].…”

Section: тк знаменська ов воробйова лі нікулінаunclassified

“…ЖК, які входять до складу ЖЕ для парентерального застосування, є попередниками різних медіаторів запальної та імунної реакції. Тому різні ЖЕ, представлені зараз на міжнародному ринку, мають різний вплив на вираженість імунної та запальної відповіді організму, а також на інтенсивність перекисного окислення ліпідів, що, у свою чергу, по-різному впливає на перебіг захворювання та клінічний прогноз у пацієнтів в ургентних станах [10,11].…”

Section: тк знаменська ов воробйова лі нікулінаunclassified